Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-HTK03162
- Development stage
- Preclinical
- Lead developer
- Alpha-9 Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-HTK03162 is an 18F-labeled, bisAmBF3-conjugated small molecule radiotracer targeting prostate-specific membrane antigen (PSMA). It incorporates a novel lysine-urea-2-aminoadipic acid (Lys-urea-Aad) pharmacophore, which replaces the traditional lysine-urea-glutamic acid (Lys-urea-Glu) pharmacophore found in other PSMA-targeting agents like 18F-DCFPyL. This structural modification significantly reduces off-target uptake in normal organs, particularly the kidneys and salivary glands, while maintaining high tumor uptake. Developed by researchers at BC Cancer and the University of British Columbia, and licensed to Alpha-9 Oncology, 18F-HTK03162 is being evaluated for positron emission tomography (PET) imaging of prostate cancer and potentially primary clear cell renal cell carcinoma.
- Other names
- 18F-labeled bisAmBF3-conjugated PSMA-targeting tracer18F-labeled bisAmBF3-conjugated PSMA-targeting tracer derived from the Lys-urea-Aad pharmacophore
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 18F-HTK03162.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-HTK03162.